Escherichia coli: placing resistance to third-generation cephalosporins and fluoroquinolones in Australia and New Zealand into perspective
Rhys T White
+ Author Affiliations
- Author Affiliations
School of Chemistry and Molecular Biosciences and Australian Infectious Disease Research Centre, The University of Queensland, Brisbane, Qld 4072, Australia; and Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Qld 4072, Australia. Tel.: +61 7 3365 8549; Email: rhystwhite@gmail.com
Microbiology Australia 42(3) 104-110 https://doi.org/10.1071/MA21031
Submitted: 25 March 2021 Accepted: 21 July 2021 Published: 8 September 2021
Journal Compilation © The Authors 2021 Open Access CC BY-NC-ND, published (by CSIRO Publishing) on behalf of the ASM
Abstract
At least 300 million urinary tract infections (UTIs) occur annually worldwide. Uropathogenic Escherichia coli (UPEC) are the leading cause of UTIs. The discovery of antibiotics has revolutionised modern medicine. Yet, overusing antibiotics has accelerated the emergence of antimicrobial resistance (AMR), with UPEC driving the dissemination of AMR globally. Resistance to broad-spectrum antibiotics like third-generation cephalosporins (3GCs) and fluoroquinolones threatens public health. Extended-spectrum β-lactamase (ESBL)-producing E. coli precipitate resistance, particularly when these antibiotics are used as empirical therapies against UPEC. In response, the Centers for Disease Control and Prevention in the United States have listed ESBL-producing Enterobacterales, such as E. coli as a severe threat. Additionally, the World Health Organization have classified 3GCs and fluoroquinolones as the highest priority (critically important antimicrobials), where these therapies are only recommended following susceptibility testing. The present report demonstrates the distributions of E. coli cases with resistance to 3GC and fluoroquinolones in Australia and New Zealand and contextualises trends with European reports. This investigation emphasises the value of epidemiology and the justification of evidence-based interventions using data as an essential resource for reducing resistance to our ‘first-line’ antibiotics.
References
[1] Centers for Disease Control and Prevention (2019) Antibiotic resistance threats in the United States, 2019. US Department of Health and Human Services, Centres for Disease Control and Prevention: Atlanta, GA, USA. https://www.cdc.gov/drugresistance/biggest-threats.html (accessed 9 July 2021).[2] O’Neill J. (2014) Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Wellcome Trust & UK Government: London, UK. https://amr-review.org/Publications.html (accessed 9 July 2021).
[3] Holmberg, S.D. et al. (1987) Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9, 1065–1078.
| Health and economic impacts of antimicrobial resistance.Crossref | GoogleScholarGoogle Scholar | 3321356PubMed |
[4] Munoz-Price, L.S. et al. (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13, 785–796.
| Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.Crossref | GoogleScholarGoogle Scholar | 23969216PubMed |
[5] Gilbert, L. et al. (2014) Healthcare infection prevention and control really is everyone’s business. Microbiol. Aust. 35, 3–4.
| Healthcare infection prevention and control really is everyone’s business.Crossref | GoogleScholarGoogle Scholar |
[6] Organisation for Economic Co-operation and Development (2021) Exchange rates (indicator). Organisation for Economic Co-operation and Development: Paris, France. https://data.oecd.org/conversion/exchange-rates.htm (updated 6 July 2021; accessed 9 July 2021).
[7] World Health Organization & WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) (2017) Critically important antimicrobials for human medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance due to non-human use. 5th edn. World Health Organization: Geneva, Switzerland. https://apps.who.int/iris/handle/10665/255027 (accessed 9 July 2021).
[8] The Institute of Environmental Science and Research Ltd (2003) Extended-spectrum β-lactamases (ESBLs) in Enterobacteriaceae confirmed in 2002. Wellington, New Zealand: Institute of Environmental Science and Research Ltd. https://surv.esr.cri.nz/antimicrobial/esbl.php (accessed 9 July 2021).
[9] The Institute of Environmental Science and Research Ltd (2008) Annual survey of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, 2007. Wellington, New Zealand: Institute of Environmental Science and Research Ltd. https://surv.esr.cri.nz/antimicrobial/esbl.php (accessed 9 July 2021).
[10] Dyet, K. et al. (2015) Annual survey of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, 2014. Institute of Environmental Science and Research Ltd: Wellington, New Zealand. https://surv.esr.cri.nz/antimicrobial/esbl.php (accessed 9 July 2021).
[11] Australian Commission on Safety and Quality in Health Care (2019) AURA 2019: third Australian report on antimicrobial use and resistance in human health. Australian Commission on Safety and Quality in Health Care: Sydney, NSW, Australia. https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system/aura-2019 (accessed 9 July 2021).
[12] Leach, A.J. et al. (2021) Otitis media guidelines for Australian Aboriginal and Torres Strait Islander children: summary of recommendations. Med. J. Aust. 214, 228–233.
| Otitis media guidelines for Australian Aboriginal and Torres Strait Islander children: summary of recommendations.Crossref | GoogleScholarGoogle Scholar | 33641192PubMed |
[13] James, S.L. et al. (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858.
| Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.Crossref | GoogleScholarGoogle Scholar |
[14] Harding, G.K.M. and Ronald, A.R. (1994) The management of urinary infections – what have we learned in the past decade. Int. J. Antimicrob. Agents 4, 83–88.
| The management of urinary infections – what have we learned in the past decade.Crossref | GoogleScholarGoogle Scholar |
[15] Australian Group on Antimicrobial Resistance (2019) Gram-negative Sepsis Outcome Program 2018 report. Australian Group on Antimicrobial Resistance: Sydney, NSW, Australia. https://www.safetyandquality.gov.au/publications-and-resources/resource-library/agar-sepsis-outcome-programs-2018-report (accessed 9 July 2021).
[16] Jarvis, T.R. et al. (2014) Assessment and management of lower urinary tract infection in adults. Aust. Prescr. 37, 7–9.
| Assessment and management of lower urinary tract infection in adults.Crossref | GoogleScholarGoogle Scholar |
[17] Wawrysiuk, S. et al. (2019) Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance – non-antibiotic approaches: a systemic review. Arch. Gynecol. Obstet. 300, 821–828.
| Prevention and treatment of uncomplicated lower urinary tract infections in the era of increasing antimicrobial resistance – non-antibiotic approaches: a systemic review.Crossref | GoogleScholarGoogle Scholar | 31350663PubMed |
[18] Forde, B.M. et al. (2019) Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection. Nat. Commun. 10, 3643.
| Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection.Crossref | GoogleScholarGoogle Scholar | 31409795PubMed |
[19] Woodford, H.J. and George, J. (2009) Diagnosis and management of urinary tract infection in hospitalized older people. J. Am. Geriatr. Soc. 57, 107–114.
| Diagnosis and management of urinary tract infection in hospitalized older people.Crossref | GoogleScholarGoogle Scholar | 19054190PubMed |
[20] Statistics New Zealand (2019) Estimated total population by sex, year ended 31 December 1926–2018 and 30 June 1937–2018. Statistics New Zealand: Wellington, New Zealand. https://www.stats.govt.nz/topics/population (accessed 9 July 2021).
[21] Australian Bureau of Statistics (2019) ‘Table 59. Estimated resident population by single year of age, Australia’ [time series spreadsheet], Australian demographic statistics. Australian Bureau of Statistics: Canberra, ACT, Australia. https://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202019 (updated 19 December 2019; accessed 9 July 2021).
[22] European Centre for Disease Prevention and Control (2017) Antimicrobial resistance surveillance in Europe 2016: annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). European Centre for Disease Prevention and Control: Stockholm, Sweden. https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016 (accessed 9 July 2021).
[23] Australian Commission on Safety and Quality in Health Care (2016) Antimicrobial prescribing practice in Australian hospitals: results of the 2015 National Antimicrobial Prescribing Survey. Australian Commission on Safety and Quality in Health Care: Sydney, NSW, Australia. https://www.safetyandquality.gov.au/publications-and-resources/resource-library/antimicrobial-prescribing-practice-australian-hospitals-results-2015-hospital-national-antimicrobial-prescribing-survey (accessed 9 July 2021).
[24] Laxminarayan, R. and Heymann, D.L. (2012) Challenges of drug resistance in the developing world. BMJ 344, e1567.
| Challenges of drug resistance in the developing world.Crossref | GoogleScholarGoogle Scholar | 22491075PubMed |
[25] Laxminarayan, R. et al. (2013) Antibiotic resistance-the need for global solutions. Lancet Infect. Dis. 13, 1057–1098.
| Antibiotic resistance-the need for global solutions.Crossref | GoogleScholarGoogle Scholar | 24252483PubMed |
[26] Organisation for Economic Co-operation and Development (2011) Health at a Glance 2011: OECD Indicators. Organisation for Economic Co-operation and Development Publishing: Paris, France. https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2011_health_glance-2011-en (accessed 9 July 2021).
[27] Williamson, D.A. et al. (2016) Antibiotic consumption in New Zealand, 2006–2014. The Institute of Environmental Science and Research Ltd: Porirua, New Zealand. https://surv.esr.cri.nz/surveillance/antibiotic_consumption.php?we_objectID=4331 (accessed 9 July 2021).
[28] Heffernan, H. et al. (2006) Prevalence of extended-spectrum β-lactamases among urinary Escherichia coli and Klebsiella in New Zealand in 2006. Institute of Environmental Science and Research Ltd: Porirua, New Zealand. https://surv.esr.cri.nz/antimicrobial/esbl.php (accessed 9 July 2021).
[29] Heffernan, H. et al. (2018) 2016 survey of extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrobial Reference Laboratory and Health Group, Institute of Environmental Science and Research Ltd: Porirua, New Zealand. https://surv.esr.cri.nz/antimicrobial/esbl.php (accessed 9 July 2021).
